Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.1K
Overview
45.1K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

106
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
106
Cancer Vaccines01:30

Cancer Vaccines

469
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
469

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global vaccine development.

Nature medicine·2026
Same author

Increased burden of invasive group A streptococcal disease among Australian children, 2023-2024: a prospective cohort study.

The Lancet regional health. Western Pacific·2026
Same author

Antibody responses against bacterial glycans affinity mature and diversify in germinal centers.

Immunity·2026
Same author

The invasive non-typhoidal Salmonella vaccine landscape: Innovations and challenges ahead.

Vaccine·2026
Same author

Clinical decision rules for diagnosis of Streptococcus pyogenes sore throat in Fiji: a prospective diagnostic accuracy study.

The Lancet regional health. Western Pacific·2025
Same author

Estimating the economic burden of invasive non-typhoidal <i>Salmonella</i> infections in low- and middle-income countries.

BMJ global health·2025
Same journal

Muscle macrophage regenerative response after squalene-adjuvanted influenza vaccination is associated with type II-skewed response and is reduced with age.

NPJ vaccines·2026
Same journal

Modeling time-varying efficacy of RTS,S/AS01 malaria vaccine across trial settings.

NPJ vaccines·2026
Same journal

EGFR mimotope alleviates renal fibrosis by promoting EGFR/RPL6/PCBP2 ternary complex formation.

NPJ vaccines·2026
Same journal

Epitope-selective vaccine designs to elicit protective antibodies against the Plasmodium falciparum circumsporozoite protein.

NPJ vaccines·2026
Same journal

Oral contraceptive usage among healthcare workers and its impact on COVID-19 booster vaccination immunogenicity.

NPJ vaccines·2026
Same journal

Mapping SARS-CoV-2 immunity after an XBB.1.5 booster by antigenic cartography of merged human and hamster sera.

NPJ vaccines·2026
See all related articles

Related Experiment Video

Updated: Aug 10, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K

The Streptococcus pyogenes vaccine landscape.

Donald R Walkinshaw1, Meghan E E Wright2, Anne E Mullin2

  • 1Shift Health, Toronto, Canada. dwalkinshaw@shifthealth.com.

NPJ Vaccines
|February 14, 2023
PubMed
Summary
This summary is machine-generated.

Developing a Streptococcus pyogenes (Group A Strep) vaccine faces challenges, but eight candidates are in development. The Strep A Vaccine Global Consortium (SAVAC) aims to accelerate progress against this pathogen.

More Related Videos

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.1K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.3K

Related Experiment Videos

Last Updated: Aug 10, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.1K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.3K

Area of Science:

  • Microbiology
  • Vaccinology
  • Infectious Diseases

Background:

  • Streptococcus pyogenes (Group A Streptococcus) causes significant global disease burden.
  • Vaccine development for S. pyogenes has historically faced scientific, regulatory, and commercial hurdles.
  • The current vaccine pipeline for S. pyogenes remains limited despite ongoing needs.

Purpose of the Study:

  • To review the historical progress in S. pyogenes vaccine development.
  • To highlight current vaccine candidates and their developmental status.
  • To emphasize key priorities and the role of the Strep A Vaccine Global Consortium (SAVAC) in advancing S. pyogenes vaccine research.

Main Methods:

  • Review of historical S. pyogenes vaccine development efforts.
  • Analysis of the current S. pyogenes vaccine candidate pipeline.
  • Discussion of the establishment and objectives of the Strep A Vaccine Global Consortium (SAVAC).

Main Results:

  • Eight S. pyogenes vaccine candidates are currently in development, including M protein-based and non-M protein antigen-based approaches.
  • Candidates have shown preclinical protection; one has completed Phase 1 trials for safety and immunogenicity.
  • Several candidates are progressing towards clinical trials, indicating renewed momentum in the field.

Conclusions:

  • Despite persistent barriers, S. pyogenes vaccine development is experiencing a resurgence.
  • The SAVAC initiative is crucial for coordinating efforts and accelerating the development of effective S. pyogenes vaccines.
  • Continued focus on key priorities and collaborative efforts is essential to overcome challenges and deliver a much-needed vaccine.